Company News: Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO 2017

– Phase I/II trial shows significant responses of HPV16-positive patients with late-stage cervical cancer

ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that an update of the results of a company-sponsored clinical Phase I/II trial in late-stage cervical cancer patients (ISA101-CervISA) will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017, Chicago, IL, USA).

A poster presentation will be held by Winald Gerritsen MD, PhD., one of the Principle Investigators of the CervISA study, on Thursday, June 3, 2017:

“Poster Session Gynecologic Cancer”: 1:15PM – 4:45PM

The data will be based on the abstract titled “Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival” (abstract no. 5525). The Company intends to publish the data in a peer-reviewed journal later this year.